Annual Total Long Term Liabilities
$190.30 M
+$7.55 M+4.13%
September 30, 2024
Summary
- As of February 8, 2025, ENTA annual total long term liabilities is $190.30 million, with the most recent change of +$7.55 million (+4.13%) on September 30, 2024.
- During the last 3 years, ENTA annual total long term liabilities has risen by +$187.11 million (+5865.61%).
- ENTA annual total long term liabilities is now at all-time high.
Performance
ENTA Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$190.30 M
-$1.37 M-0.72%
September 30, 2024
Summary
- As of February 8, 2025, ENTA quarterly total long term liabilities is $190.30 million, with the most recent change of -$1.37 million (-0.72%) on September 30, 2024.
- Over the past year, ENTA quarterly long term liabilities has increased by +$7.55 million (+4.13%).
- ENTA quarterly long term liabilities is now -1.31% below its all-time high of $192.84 million, reached on March 31, 2024.
Performance
ENTA Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
ENTA Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.1% | +4.1% |
| 3 y3 years | +5865.6% | +5865.6% |
| 5 y5 years | +3925.0% | +5865.6% |
ENTA Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +5865.6% | -1.3% | +987.6% |
| 5 y | 5-year | at high | +5865.6% | -1.3% | +5865.6% |
| alltime | all time | at high | +9516.1% | -1.3% | >+9999.0% |
Enanta Pharmaceuticals Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | $190.30 M(+4.1%) | $190.30 M(-0.7%) |
| Jun 2024 | - | $191.68 M(-0.6%) |
| Mar 2024 | - | $192.84 M(+10.7%) |
| Dec 2023 | - | $174.21 M(-4.7%) |
| Sep 2023 | $182.75 M(+653.7%) | $182.75 M(-3.4%) |
| Jun 2023 | - | $189.16 M(+659.6%) |
| Mar 2023 | - | $24.90 M(+5.1%) |
| Dec 2022 | - | $23.70 M(-2.3%) |
| Sep 2022 | $24.25 M(+660.2%) | $24.25 M(+0.4%) |
| Jun 2022 | - | $24.16 M(+38.1%) |
| Mar 2022 | - | $17.50 M(-4.5%) |
| Dec 2021 | - | $18.32 M(+474.3%) |
| Sep 2021 | $3.19 M(-50.1%) | $3.19 M(-19.5%) |
| Jun 2021 | - | $3.96 M(-22.6%) |
| Mar 2021 | - | $5.12 M(-14.3%) |
| Dec 2020 | - | $5.97 M(-6.6%) |
| Sep 2020 | $6.39 M(+35.3%) | $6.39 M(-11.6%) |
| Jun 2020 | - | $7.23 M(-9.5%) |
| Mar 2020 | - | $7.99 M(-16.3%) |
| Dec 2019 | - | $9.55 M(+101.9%) |
| Sep 2019 | $4.73 M(+4.5%) | $4.73 M(-3.2%) |
| Jun 2019 | - | $4.89 M(+0.2%) |
| Mar 2019 | - | $4.88 M(+2.7%) |
| Dec 2018 | - | $4.75 M(+5.0%) |
| Sep 2018 | $4.52 M | $4.52 M(+8.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $4.16 M(+0.5%) |
| Mar 2018 | - | $4.13 M(+5.5%) |
| Dec 2017 | - | $3.92 M(-1.5%) |
| Sep 2017 | $3.98 M(+15.3%) | $3.98 M(+3.4%) |
| Jun 2017 | - | $3.85 M(+1.5%) |
| Mar 2017 | - | $3.79 M(+0.3%) |
| Dec 2016 | - | $3.78 M(+9.5%) |
| Sep 2016 | $3.45 M(+9.5%) | $3.45 M(+2.8%) |
| Jun 2016 | - | $3.36 M(+5.2%) |
| Mar 2016 | - | $3.19 M(-1.1%) |
| Dec 2015 | - | $3.23 M(+2.4%) |
| Sep 2015 | $3.15 M(+56.4%) | $3.15 M(+44.6%) |
| Jun 2015 | - | $2.18 M(+16.0%) |
| Mar 2015 | - | $1.88 M(+1.7%) |
| Dec 2014 | - | $1.85 M(-8.3%) |
| Sep 2014 | $2.02 M(+1.8%) | $2.02 M(-12.1%) |
| Jun 2014 | - | $2.29 M(+3.7%) |
| Mar 2014 | - | $2.21 M(+10.0%) |
| Dec 2013 | - | $2.01 M(+1.6%) |
| Sep 2013 | $1.98 M(-20.8%) | $1.98 M(-14.7%) |
| Jun 2013 | - | $2.32 M(+0.8%) |
| Mar 2013 | - | $2.30 M(-7.7%) |
| Dec 2012 | - | $2.49 M(-0.2%) |
| Sep 2012 | $2.50 M(+25.4%) | $2.50 M(-98.4%) |
| Jun 2012 | - | $160.66 M(+7961.0%) |
| Sep 2011 | $1.99 M | $1.99 M |
FAQ
- What is Enanta Pharmaceuticals annual total long term liabilities?
- What is the all time high annual total long term liabilities for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals annual total long term liabilities year-on-year change?
- What is Enanta Pharmaceuticals quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Enanta Pharmaceuticals?
- What is Enanta Pharmaceuticals quarterly long term liabilities year-on-year change?
What is Enanta Pharmaceuticals annual total long term liabilities?
The current annual total long term liabilities of ENTA is $190.30 M
What is the all time high annual total long term liabilities for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high annual total long term liabilities is $190.30 M
What is Enanta Pharmaceuticals annual total long term liabilities year-on-year change?
Over the past year, ENTA annual total long term liabilities has changed by +$7.55 M (+4.13%)
What is Enanta Pharmaceuticals quarterly total long term liabilities?
The current quarterly long term liabilities of ENTA is $190.30 M
What is the all time high quarterly long term liabilities for Enanta Pharmaceuticals?
Enanta Pharmaceuticals all-time high quarterly total long term liabilities is $192.84 M
What is Enanta Pharmaceuticals quarterly long term liabilities year-on-year change?
Over the past year, ENTA quarterly total long term liabilities has changed by +$7.55 M (+4.13%)